Abstract | BACKGROUND:
Gemcitabine has been shown to exhibit significant clinical activity against pancreatic cancer and has become a first-line chemotherapeutic for this disease in recent years. However, there are still many patients who do not respond to this treatment and it is expected to improve the clinical outcome if we can develop a method to predict the efficacy of gemcitabine before treatment. The purpose of this study was to determine novel factors that make pancreatic cancer resistant to gemcitabine. MATERIALS AND METHODS: RESULTS: CONCLUSIONS: Analysis of Annexin II expression in cancer tissues may predict the clinical outcome of gemcitabine treatment, leading to the development of a new method for tailor-made treatment for this disease.
|
Authors | Shigetsugu Takano, Akira Togawa, Hideyuki Yoshitomi, Takashi Shida, Fumio Kimura, Hiroaki Shimizu, Hiroyuki Yoshidome, Masayuki Ohtsuka, Atsushi Kato, Takeshi Tomonaga, Fumio Nomura, Masaru Miyazaki |
Journal | Annals of surgical oncology
(Ann Surg Oncol)
Vol. 15
Issue 11
Pg. 3157-68
(Nov 2008)
ISSN: 1534-4681 [Electronic] United States |
PMID | 18712570
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Annexin A2
- Antimetabolites, Antineoplastic
- RNA, Messenger
- RNA, Small Interfering
- Deoxycytidine
- Gemcitabine
|
Topics |
- Adenocarcinoma
(drug therapy, metabolism, surgery)
- Aged
- Annexin A2
(genetics, metabolism)
- Antimetabolites, Antineoplastic
(therapeutic use)
- Blotting, Western
- Carcinoma, Adenosquamous
(drug therapy, metabolism, surgery)
- Carcinoma, Pancreatic Ductal
(drug therapy, metabolism, surgery)
- Cell Survival
(drug effects)
- Chemotherapy, Adjuvant
- Deoxycytidine
(analogs & derivatives, therapeutic use)
- Drug Resistance, Neoplasm
- Female
- Gene Expression Regulation, Neoplastic
(drug effects)
- Humans
- Immunoenzyme Techniques
- Male
- Middle Aged
- Neoplasm Invasiveness
- Neoplasm Recurrence, Local
(diagnosis, drug therapy, surgery)
- Pancreatic Neoplasms
(drug therapy, metabolism, surgery)
- Prognosis
- RNA, Messenger
(genetics, metabolism)
- RNA, Small Interfering
(pharmacology)
- Reverse Transcriptase Polymerase Chain Reaction
- Survival Rate
- Tumor Cells, Cultured
- Gemcitabine
|